Wenjian Liao

Sun Yat-sen University

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Lin Huang

Sun Yat-sen Memorial Hospital

Tianxin Lin

Sun Yat-sen Memorial Hospital

Tenghao Yang

Sun Yat-sen Memorial Hospital

Jian Huang

Yangtze University

Xiaodong Huang

Sun Yat-sen Memorial Hospital

Yiyu Sheng

Sun Yat-sen University

Zhixing Guo

Yunnan University

Ziwei Ou

Sun Yat-sen University

Wenlong Zhong

Sun Yat-sen Memorial Hospital

Bo Wang

Sun Yat-sen University

Cooperative Institutions

Sun Yat-sen University

Sun Yat-sen Memorial Hospital

Shanghai Jiao Tong University

Chinese Academy of Sciences

Guangzhou Medical University

Chinese Academy of Medical Sciences & Peking Union Medical College

University of Chinese Academy of Sciences

Guangzhou Experimental Station

Zhejiang Chinese Medical University

Shenzhen Bay Laboratory

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Supplementary Table S6 from Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant

Bo Wang Ziwei Ou Wenlong Zhong Lin Huang Wenjian Liao

Clinicopathological characteristics of Cohort ⅤI patients with urothelial cell carcinoma of the bladder

TLR3

10.1158/2326-6066.24709671

Cite

Citations (0)

Supplementary Figure S8 from Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant

Bo Wang Ziwei Ou Wenlong Zhong Lin Huang Wenjian Liao

Combination (combo) of VISTA mAb 13F3/sODN-dsRNA with TGF-β1mAb induced TME changes in MB49 mouse tumors

TLR3

10.1158/2326-6066.24709707

Cite

Citations (0)

Supplementary Table S5 from Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant

Bo Wang Ziwei Ou Wenlong Zhong Lin Huang Wenjian Liao

Clinicopathological characteristics of Cohort Ⅴ patients with urothelial cell carcinoma of the bladder

TLR3

Table (database)

10.1158/2326-6066.24709674

Cite

Citations (0)

Supplementary Table S12 from Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant

Bo Wang Ziwei Ou Wenlong Zhong Lin Huang Wenjian Liao

Demographics of Cohort Ⅱ UCB Patients and tumor characteristics stratified by VISTA expression on immune cells

Demographics

TLR3

10.1158/2326-6066.24709689.v1

Cite

Citations (0)

Supplementary Figure S2 from Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant

Bo Wang Ziwei Ou Wenlong Zhong Lin Huang Wenjian Liao

Overall survival (OS) was analyzed with the Kaplan-Meier method stratifying 144 Cohort II UCB patients according to high or low levels of VISTA+ endothelial cells (ECs, A), or tumor cells (TCs, B)

TLR3

10.1158/2326-6066.24709728.v1

Cite

Citations (0)

Structure and mechanism of a methyltransferase ribozyme

Nature Chemical Biology (2022)

Jie Deng Timothy J. Wilson Jia Wang Xuemei Peng Mengxiao Li

Abstract Known ribozymes in contemporary biology perform a limited range of chemical catalysis, but in vitro selection has generated species that catalyze a broader range of chemistry; yet, there have been few structural and mechanistic studies of selected ribozymes. A ribozyme has recently been selected that can catalyze a site-specific methyl transfer reaction. We have solved the crystal structure of this ribozyme at a resolution of 2.3 Å, showing how the RNA folds to generate a very specific binding site for the methyl donor substrate. The structure immediately suggests a catalytic mechanism involving a combination of proximity and orientation and nucleobase-mediated general acid catalysis. The mechanism is supported by the pH dependence of the rate of catalysis. A selected methyltransferase ribozyme can thus use a relatively sophisticated catalytic mechanism, broadening the range of known RNA-catalyzed chemistry.

Hairpin ribozyme

Nucleobase

VS ribozyme

Nucleic acid structure

10.1038/s41589-022-00982-z

Cite

Citations (32)

Supplementary Figure S2 from Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant

Bo Wang Ziwei Ou Wenlong Zhong Lin Huang Wenjian Liao

TLR3

10.1158/2326-6066.24709728

Cite

Citations (0)

Supplementary Table S3 from Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant

Bo Wang Ziwei Ou Wenlong Zhong Lin Huang Wenjian Liao

Clinicopathological characteristics of Cohort Ⅲ patients with urothelial cell carcinoma of the bladder

TLR3

10.1158/2326-6066.24709680

Cite

Citations (0)

Ribocentre-switch: a database of riboswitches

Nucleic Acids Research (2023)

Fan Bu Xiaowei Lin Wenjian Liao Zhizhong Lu Yuanlin He

Abstract Riboswitches are regulatory elements found in the untranslated regions (UTRs) of certain mRNA molecules. They typically comprise two distinct domains: an aptamer domain that can bind to specific small molecules, and an expression platform that controls gene expression. Riboswitches work by undergoing a conformational change upon binding to their specific ligand, thus activating or repressing the genes downstream. This mechanism allows gene expression regulation in response to metabolites or small molecules. To systematically summarise riboswitch structures and their related ligand binding functions, we present Ribocentre-switch, a comprehensive database of riboswitches, including the information as follows: sequences, structures, functions, ligand binding pockets and biological applications. It encompasses 56 riboswitches and 26 orphan riboswitches from over 430 references, with a total of 89 591 sequences. It serves as a good resource for comparing different riboswitches and facilitating the identification of potential riboswitch candidates. Therefore, it may facilitate the understanding of RNA structural conformational changes in response to ligand signaling. The database is publicly available at https://riboswitch.ribocentre.org.

Riboswitch

Aptamer

10.1093/nar/gkad891

Cite

Citations (7)

Effective Antitumor Immunity Can Be Triggered by Targeting VISTA in Combination with a TLR3-Specific Adjuvant

Cancer Immunology Research (2023)

Bo Wang Ziwei Ou Wenlong Zhong Lin Huang Wenjian Liao

Abstract Resistance to anti–PD-1/PD-L1 treatment is often associated with accumulation of intratumoral inhibitory macrophages. V-domain immunoglobulin suppressor of T-cell activation (VISTA) is a nonredundant immune checkpoint that can induce both T-cell and myeloid-cell immunosuppression. In this study, we found that high levels of VISTA+ immune cells were associated with advanced stage bladder cancer and predicted poor survival in patients. A combination of high infiltration of VISTA+ immune cells and PD-L1+ immune cells or PD-1+ T cells predicted the worst survival. Flow cytometry and multiplex immunofluorescence analyses confirmed that VISTA expression was higher in macrophages than in T cells or neutrophils, and only VISTA+CD163+ macrophage density predicted poor prognosis in patients with bladder cancer. Toll-like receptor (TLR) agonists are known to trigger the innate immune response in macrophages. We found that the VISTA-specific mAb 13F3 augmented the ability of a TLR3-specific adjuvant to induce macrophage activation in vitro. In the MB49 syngeneic mouse model of bladder cancer, treatment with 13F3 curbed tumor growth and prolonged survival when combined with a TLR3-specific adjuvant. The combination treatment reduced the intratumoral frequency of CD206+ anti-inflammatory macrophages and levels of the immunosuppressive molecule TGFβ1, but it upregulated expression of immunostimulatory molecules (Ifna, Ifnb, and Trail) and increased the CD8+ T cell/regulatory T-cell ratio. These findings indicate that elevated VISTA expression in immune cells, particularly macrophages, is associated with an unfavorable prognosis in patients with bladder cancer and suggest that targeting VISTA in combination with a TLR3-specific adjuvant has translational potential.

TLR3

Myeloid-derived Suppressor Cell

10.1158/2326-6066.cir-23-0117

Cite

Citations (6)